Journal
CANCER BIOLOGY & THERAPY
Volume 3, Issue 12, Pages 1225-1231Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/cbt.3.12.1222
Keywords
breast cancer; DNA methylation; heterochromatin; satellite DNA; tumor progression
Categories
Funding
- NCI NIH HHS [R01-CA81506] Funding Source: Medline
Ask authors/readers for more resources
Hypomethylation of some portions of the genome and hypermethylation of others are very frequent attributes of human cancer. We previously showed that cancer-associated DNA hypomethylation often involves satellite 2 (Sat2), the main DNA component of the large juxtacentromeric (centromere-adjacent) heterochromatin of chromosome 1. In this study, we compared methylation of Sat2 and centromeric satellite DNA (Sat alpha) as well as overall genomic methylation in 41 breast adenocarinomas of known tumor grade and stage, 16 non-neoplastic breast tissues (mostly fibroadenomas), and a variety of normal somatic tissue controls. The cancers were significantly hypomethylated at Sat2 relative to the fibroadenomas or normal somatic tissues and at Sat alpha relative to the normal somatic tissues. However, unlike Sat2, Sat alpha did not display significant differences in methylation between the cancers and the non-neoplastic breast tissues. Therefore, hypomethylation at Sat2 is a much better marker of breast cancer than is Sat alpha hypomethylation. There was a significant association of Sat2 hypomethylation with global DNA hypomethylation in the cancers but not with tumor grade, stage, axillary lymph node involvement, or hormone receptor status. Extensive cancer-associated hypomethylation of juxtacentromeric satellite DNA and global DNA hypomethylation were common even in grade-1 or stage-1 carcinomas, which suggests that demethylation of the genome is an early event in breast carcinogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available